The role of ADP and purinergic receptors
Adenosine diphosphate (ADP) is released upon platelet activation and acts as a stimulus for neighboring blood platelets. Formation of a complete and stable thrombus requires the coordinated action of two types of purinergic receptors coupled with G-proteins:
- P2Y1 receptors (coupled with Gq proteins). Responsible for the initial phase of activation. They trigger phospholipase C, leading to the release of calcium ions from intracellular stores. As a result, the platelet changes shape (spherization occurs) and reversible aggregation begins.
- P2Y12 receptors (coupled with Gi proteins). They inhibit adenylyl cyclase activity, decrease intracellular cAMP levels, and increase cytoplasmic calcium concentration. They complete the process by altering the conformation of GPIIb-IIIa glycoproteins (fibrinogen receptors) and inducing irreversible aggregation. Furthermore, stimulation of these receptors enhances the effect of other thrombogenic inducers, such as collagen, thrombin, and thromboxane A2.
Classification of P2Y12 receptor inhibitors
Drugs that selectively block the final stages of platelet activation are divided into two main groups based on their chemical structure:
- Thienopyridine derivatives: clopidogrel, prasugrel, ticlopidine.
- Substances of different chemical structure: ticagrelor, cangrelor, elinogrel.
Mechanism of action of thienopyridines
Ticlopidine and clopidogrel are pharmacologically inactive on their own—they are prodrugs. In the liver, under the action of microsomal enzymes (cytochrome P450 isoforms), they are converted into active metabolites containing reactive thiol groups.
The pharmacodynamic cascade develops as follows:
- The active metabolite forms a covalent (irreversible) bond with the cysteine residues of the P2Y12 receptor.
- The receptor is blocked, eliminating the stimulating effect of ADP on the platelet.
- Cytoplasmic calcium concentration decreases.
- GPIIb-IIIa glycoproteins lose their ability to bind to fibrinogen strands.
- Platelet aggregate formation stops.
Since the bond is covalent, the antiplatelet effect persists for the lifespan of the platelet, i.e., about 7–10 days after complete discontinuation of therapy.
Features of other representatives of the group
Drugs that are not thienopyridines possess unique pharmacokinetic properties and binding mechanisms:
- Cangrelor. It is an ATP analog resistant to degradation by ectonucleotidase enzymes. Administered exclusively parenterally (intravenously as a bolus followed by infusion). It features an almost instantaneous onset of action and an extremely short half-life—only 3–6 minutes. Used in situations requiring short-term and easily controllable antiplatelet action (e.g., during coronary artery bypass grafting).
- Elinogrel. Binds to P2Y12 receptors directly and reversibly. Acts rapidly, with a duration of effect of about 12 hours (longer than cangrelor, but shorter than clopidogrel). Available in both oral and intravenous formulations.
- Ticagrelor. Officially registered in the Russian Federation (like prasugrel). An important feature is its ability to affect the P-glycoprotein transporter. This can alter the plasma concentration of other drugs that are substrates of this transporter (e.g., digoxin).
Briefly: answers to topical questions
Which specific cytochrome P450 isoenzymes are involved in clopidogrel metabolism?
A number of cytochrome P450 isoenzymes are involved in the metabolic activation of clopidogrel and sequential oxidation reactions. The CYP2C19 isoenzyme plays a key role in these processes, while CYP1A2, CYP2B6, CYP2C9, and CYP3A are also involved in the formation of the active metabolite and intermediates.
What specific side effects are characteristic of ticlopidine?
Ticlopidine is characterized by pronounced hematological toxicity, which poses the greatest danger during therapy. Side effects include neutropenia, especially in the first 3 months of treatment, as well as thrombocytopenia, agranulocytosis, and a rare severe complication in the form of aplastic anemia. Regular blood counts are required in the first months of treatment.
The concentration of which P-glycoprotein substrate drugs changes when co-administered with ticagrelor?
Co-administration with ticagrelor alters the plasma concentration of P-glycoprotein substrate drugs due to its inhibition. Digoxin is cited in the materials as a specific example of a substrate whose concentration increases, and a pharmacokinetic interaction with dabigatran etexilate is also noted, resulting in an increased concentration.
What are the full indications for the use of cangrelor?
Cangrelor is used in clinical practice in specific situations requiring short-term controllable antiplatelet effects. In particular, the drug is used during coronary artery bypass grafting.
To avoid confusing the receptors: P2Y1 is the "First step" (shape change, reversible aggregation). P2Y12 is "1-2, finish!" (irreversible aggregation, the main target for drugs).
Class and exam questions
Why does the effect of clopidogrel persist for more than a week after discontinuation?
Clopidogrel belongs to thienopyridines. Its active metabolites bind to receptors covalently and irreversibly, which is why the antiplatelet effect lasts for the entire lifespan of the platelet (7–10 days).
What is the main difference between cangrelor and other drugs in the group?
Cangrelor is administered exclusively intravenously, acts instantly, and has a half-life of only 3–6 minutes. This allows clinicians to rapidly manage the antiplatelet effect during surgical procedures.
Are thienopyridines direct receptor inhibitors?
No, these are prodrugs. To exhibit activity, they must undergo hepatic metabolism involving cytochrome P-450 enzymes, where their active metabolites are formed.
What is the role of P2Y1 receptors?
They trigger the initial phase of platelet activation, causing spherization and reversible aggregation due to the release of calcium from intracellular stores.
What else to study on this topic
- Interaction of ticagrelor with P-glycoprotein substrates (using digoxin as an example)
- The role of specific cytochrome P-450 isoenzymes in clopidogrel activation
- The mechanism of conformational changes in GPIIb-IIIa glycoproteins upon cAMP level reduction
- Comparative characteristics of prasugrel and clopidogrel
- Clinical indications for the use of cangrelor in cardiac surgery
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "P2Y12 receptor antagonists" and 5,304 more pages on this subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs affecting hemostasis and thrombosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.